Randomized Clinical Trial
Copyright ©The Author(s) 2015.
World J Gastroenterol. Nov 21, 2015; 21(43): 12457-12467
Published online Nov 21, 2015. doi: 10.3748/wjg.v21.i43.12457
Table 3 Clinical parameters in sulforaphane and placebo group participants before and after trial, Median (interquartile range)
SF group (n = 24)
Placebo group (n = 28)
BeforeAfterBeforeAfter
BMI, kg/m225.7 (24.2-27.6)25.8 (24.2-27.3)25.9 (24.6-26.8)25.6 (24.5-26.8)a
Waist Circumference, cm86.5 (81.0-95.0)88.8 (82.5-95.0)92.3 (88.4-95.3)91.4 (88.5-97.1)
AST, IU/L37.5 (24.8-48.3)37.5 (27.0-39.8)30.0 (27.5-39.5)26.0 (22.5-42.8)
ALT, IU/L54.0 (34.5-79.0)48.5 (33.0-65.3)a41.5 (34.0-64.3)40.5 (27.0-60.5)
γ-GTP, IU/L51.5 (40.8-91.3)50.0 (37.8-85.3)a52.0 (39.5-127.5)53.0 (37-99)
Alb, g/dL4.6 (4.4-4.9)4.5 (4.3-4.7)a4.6 (4.5-4.7)4.6 (4.5-4.8)
TB, mg/dL0.9 (0.6-1.1)0.9 (0.7-1.2)0.9 (0.6-1.1)0.8 (0.7-1.0)
ALP, IU/L210 (168-248)182 (166-140)a230 (206-274)231 (214-281)
ChE, IU/L390 (359-436)388 (358-421)a398 (369-458)406 (370-424)
Ferritin, ng/mL281 (131-381)216 (136-365)231 (162-322)215 (168-321)
UA, mg/dL6.1 (5.5-7.0)6.0 (5.4-6.8)6.4 (5.4-6.8)6.1 (5.6-6.7)
TG, mg/dL146 (118-193)135 (95.5-208)133 (99.3-166)113 (83.0-160)
TC, mg/dL201 (182-219)194 (184-211)a196 (183-224)207 (184-225)
HDL-C, mg/dL50.0 (44.0-59.0)48.5 (44.8-54.0)47.5 (44.8-58.0)49.5 (45.0-57.0)
LDL-C, mg/dL123 (107-138)123 (111-141)125 (116-142)137 (118-146)
HbA1c, %5.7 (5.4-6.1)5.7 (5.5-6.0)5.8 (5.5-6.1)5.8 (5.5-6.1)
FBS, mg/dL105 (99.8-113)106 (101-115)105 (99-115)106 (97.5-115)
hs-CRP, mg/dL0.067 (0.036-0.13)0.059 (0.031-0.13)0.056 (0.037-0.14)0.068 (0.028-0.15)
8-OHdG, ng/mg-CRE6.8 (5.5-9.0)5.5 (4.9-6.7)a6.6 (5.3-8.4)6.1 (4.7-7.6)
Adiponectin, μg/mL6.1 (4.8-7.4)4.8 (4.1-7.7)a6.3 (4.6-9.5)6.1 (4.6-7.9)a
Leptin, ng/mL5.9 (4.2-7.5)5.8 (3.0-8.7)7.3 (5.2-11.4)6.6 (4.1-10.1)